Bristol-Myers Squibb have recently announced the failure of the drug Opdivo® (nivolumab) to show a clinically significant effect in the treatment of small-cell lung cancer.
Approximately 1 in 4 patients being treated in the community have received DNA matched treatment from comprehensive genomic profiling results, indicating that precision medicine is now increasingly utilized in settings other than specialist hospital environments.
In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.
A new study, published in CNS Oncology estimates the survival benefit of adding tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation; find out more in this article from Immunotherapy.